HEALTH OF WOMAN.2015.3(99):105–109; doi 10.15574/HW.2015.99.105 
 

Vascular endothelial growth factor and endothelium-dependent dilation in patients with polycystic ovary syndrome with different body mass 
 

Mogylnytska L. A.

Khmelnytskyi regional hospital 
 

The study found increasing of serum levels of vascular endothelial growth factor (VEGF) and weakening of endothelium-dependent dilation in patients with polycystic ovary syndrome (PCOS) obese and normal weight compared with the control group. In the group of patients with PCOS as obese and normal weight found correlation between the serum levels of EMAP-II and BMI, HOMA index, lipid metabolism, androgens. Revealed changes may indicate the development of endothelial dysfunction in patients with PCOS and the possible relationship VEGF with these disorders. 
 

Key words: vascular endothelial growth factor, endothelium-dependent dilation, polycystic ovary syndrome, insulin resistance, endothelial dysfunction. 
 

REFERENCES

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. 2004. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin. Endocrinol. Metab. 89(6):2745–9.

2. Alpaсйs M, Luque-Ramнrez M, Martнnez-Garcнa MБ, Fernбndez-Durбn E, Бlvarez-Blasco F, Escobar-Morreale HF. 2015. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome. Fertil Steril. 10:S0015-0282(14)02530-8.

3. Celermajer DS, Sorensen KE, Gooch VM et al. 1992. Non-invasive detection of endothelial dysfunction in children and adults at risk for atherosclerosis. Lancet. 340:1111–1115. http://dx.doi.org/10.1016/0140-6736(92)93147-F

4. Corretti MC, Anderson TJ, Benjamin EJ et al. 2002. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J. Am. Coll. Cardiol. 39:257–265. http://dx.doi.org/10.1016/S0735-1097(01)01746-6

5. Corbould A. 2007. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J. Endocrinol. 192:585–594. http://dx.doi.org/10.1677/joe.1.07070; PMid:17332526

6. Deligeoroglou E, Vrachnis N, Athanasopoulos N et al. 2012. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol. Endocrinol. 28(12):974–8.

7. Ferriman D, Gallwey JD. 1962. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 21:1440–1447. http://dx.doi.org/10.1210/jcem-21-11-1440; PMid:13892577

8. Ferrara N, Chen H, Davis-Smyth T et al. 1998. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4:336–340. http://dx.doi.org/10.1038/nm0398-336; PMid:9500609

9. Juonala M, Magnussen CG, Berenson GS et al. 2011. Childhood adiposity, adult adiposity, and cardiovascular risk factors. New Engl. J. Med. 365:1876–1885. http://dx.doi.org/10.1056/NEJMoa1010112; PMid:22087679

10. Lim HS, Chong AY, Freestone B, Blann AD, Lip GY. 2005. The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease. Diabet. Med. 22(3):249–55. http://dx.doi.org/10.1111/j.1464-5491.2004.01388.x

11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Trecher DF, Turner DC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419. http://dx.doi.org/10.1007/BF00280883; PMid:3899825

12. Meldrum DR. 2002. Vascular endothelial growth factor, polycystic ovary syndrome, and ovarian hyperstimulation syndrome. Fertil. Steril. 78(6):1170–1. http://dx.doi.org/10.1016/S0015-0282(02)04244-9

13. Muolokwu E, Sanchez J, Bercaw JL et al. 2011. Paratubal cysts, obesity, and hyperandrogenism. J. Pediatr. Surg. 46:2164–2167. http://dx.doi.org/10.1016/j.jpedsurg.2011.07.011; PMid:22075351

14. Orio FJr, Palomba S, Spinelli L et al. 2004. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case–control study. J Clin. Endocrinol. Metab. 89:3696–3701. http://dx.doi.org/10.1210/jc.2003-032049; PMid:15292291

15. Otani N, Minami S, Yamoto M et al. 1999. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin. Endocrinol. Metab. 84:3845–51. http://dx.doi.org/10.1210/jcem.84.10.6025; PMid:10523040

16. Reynolds LP, Redmer DA. 1998. Expression of the angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in the ovary. J Anim. Sci. 76:1671–81.

17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum. Reprod. 2004. 19:41–47.

18. Toscani MK, Mario FM, Radavelli-Bagatini S, Spritzer PM. 2011. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. Nutr. Res. 31:97–103. http://dx.doi.org/10.1016/j.nutres.2011.01.009; PMid:21419313

19. Tzeng CR, Chang YC, Chang YC. 2014. Cluster analysis of cardiovascular and metabolic risk factors in women of reproductive age. Fertil. Steril. 101(5):1404–10.

20. Vйlez LM, Motta AB. 2014. Association between polycystic ovary syndrome and metabolic syndrome. Curr. Med. Chem. 21(35):3999–4012.

21. Vermeulen A, Verdonck L, Kaufman JM. 1999. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84:3666–3672. http://dx.doi.org/10.1210/jcem.84.10.6079; PMid:10523012

22. Wojciechowski P, Lipowska A, Rys P et al. 2012. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia. 55:2636–2645. http://dx.doi.org/10.1007/s00125-012-2638-6; http://dx.doi.org/10.1007/s00125-012-2664-4; PMid:22801903

23. Yavuz Taєlipinar M, Kiliз N, Bayraktar N et al. 2014. Endothelial dysfunction and insulin resistance in young women with polycystic ovarian syndrome. Turk. J Med. Sci. 44(5):787–91.